{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T22:18:28Z","timestamp":1783981108145,"version":"3.55.0"},"reference-count":10,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T00:00:00Z","timestamp":1084492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2004,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>This study was undertaken to evaluate the adverse consequences of recently introduced higher strength (0.4 and 2.0 mg per tablet) buprenorphine in Indian market. Buprenorphine, a partial opiate agonist and antagonist, is an emerging alternative to methadone as an agent for long\u2010term treatment of opiate dependence.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The current investigation was conducted through a multi\u2010centric post\u2010marketing surveillance (PMS)study using a structured performa from patients receiving buprenorphine as routine therapy from de\u2010addiction centres. Evaluation included subjective and objective assessments and recording of adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 5551 observations from ten centres, common subjective symptoms were generalised weakness (48.9%), sense of high (euphoria) (44.5%), muscle aches (39.5%) and relief from pain (37.2%). About 5% observations recorded systolic hypertension. Among 55 subjects where laboratory tests were conducted, 12 showed raised levels of AST ad 9 had elevated ALT. Twelve adverse events reported included seizure, epistaxis, panic attacks, constipation and dyspnoea. Significant relation was seen between duration of use and time since last dose, and total number of subjective symptoms reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Majority of the adverse effects could be understood as either effects related to intoxication or withdrawal from agonists. Copyright \u00a9 2004 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.975","type":"journal-article","created":{"date-parts":[[2004,5,14]],"date-time":"2004-05-14T12:01:49Z","timestamp":1084536109000},"page":"615-619","source":"Crossref","is-referenced-by-count":12,"title":["Post\u2010marketing surveillance of buprenorphine"],"prefix":"10.1002","volume":"13","author":[{"given":"Rajat","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemraj","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pallab","family":"Maulick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mangla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2004,5,14]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1986.tb02986.x"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.6183.163"},{"key":"e_1_2_1_4_2","volume-title":"The ICD\u201010 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1992"},{"key":"e_1_2_1_5_2","first-page":"521","volume-title":"Goodman and Gillman's The Pharmacological Basis of Therapeutics","author":"Reisine T","year":"1996"},{"key":"e_1_2_1_6_2","first-page":"47","article-title":"Buprenorphine: dose related blockade of opioid challenge effects in opioid dependent humans","volume":"247","author":"Bickel WK","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1989.66"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.1998.9344753.x"},{"key":"e_1_2_1_10_2","first-page":"30","article-title":"Buprenorphine effects on human heroin self\u2010administration: an operant analysis","volume":"223","author":"Mello NK","year":"1982","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_11_2","first-page":"449","article-title":"Buprenorphine's physical dependence potential: antagonist precipitated withdrawal in humans","volume":"276","author":"Eissenberg T","year":"1996","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.975","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.975","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T23:36:46Z","timestamp":1700264206000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,5,14]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2004,9]]}},"alternative-id":["10.1002\/pds.975"],"URL":"https:\/\/doi.org\/10.1002\/pds.975","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,5,14]]}}}